3631 results for «937»

Filter By

3631 results

New data in DCB outcomes

20 May 2026 – From EuroPCR 2026

Explore emerging evidence on drug-coated balloon (DCB) outcomes, featuring intravascular lithotripsy combined with DCB in calcified small vessels, OCT-guided PCI registries, predictors of angiographic success post-sirolimus-coated balloon angioplasty, and clinical impact in multivessel coronary artery disease management.

CTO PCI: an evolving landscape

21 May 2026 – From EuroPCR 2026

Review the evolving landscape of chronic total occlusion (CTO) PCI with a focus on recent trends, contemporary management in multivessel disease, and innovative techniques such as retrograde approaches and titrated contrast recanalization. This session also addresses cost-effectiveness and drug-coated balloon (DCB) therapy outcomes from multicenter studies.

Re-intervention challenges after first aortic valve replacement

19 May 2026 – From EuroPCR 2026

Addressing the challenges of re-intervention after initial aortic valve replacement, this session highlights advanced valve-in-valve TAVI strategies, including leaflet modification techniques, management of extreme coronary obstruction risks, and complex anatomical considerations such as post-Bentall root anatomy.

fNew evidence in the treatment of calcified lesions

19 May 2026 – From EuroPCR 2026

This session presents the latest evidence on treating calcified coronary lesions, comparing intravascular lithotripsy, cutting balloons, rotational and orbital atherectomy. It includes clinical trial data on efficacy, safety, and impact on coronary microvascular function, providing a robust foundation for evidence-based decision-making in calcified lesion management.

New evidence for coronary physiology in epicardial disease

20 May 2026 – From EuroPCR 2026

Explore new evidence in coronary physiology related to epicardial disease through analyses of landmark trials and registries. Topics include five-year follow-up data from DEFINE-FLAIR and iFR-SWEDEHEART, complete revascularization in elderly myocardial infarction patients, angiography-derived versus pressure wire assessments, prognostic implications of CT angiography-derived physiology, and the...

Evidence for new devices in management of coronary artery disease

19 May 2026 – From EuroPCR 2026

This session reviews the latest evidence on new devices in coronary artery disease management. It covers outcomes from randomized controlled trials including imaging- and physiology-guided PCI with the Bioadaptor device, long-term results of thinner-strut bioresorbable scaffolds, site-specific antithrombotic therapy evaluated in the DESyne BDS Plus Trial,...

New data on intracoronary imaging-guided interventions

21 May 2026 – From EuroPCR 2026

This session presents new data on intracoronary imaging-guided interventions, comparing outcomes of angiography-derived FFR and IVUS-guided PCI over two years, as well as OCT versus IVUS for intermediate left main stenosis. It further evaluates high-risk non-culprit lesions post-myocardial infarction, the role of coronary lipid burden in...

TAVI: head-to-head trials

20 May 2026 – From EuroPCR 2026

This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

M. Pighi

Author

Michele Pighi
Bioprosthetic valve fracture in ViV-TAVR

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Paola Redaelli

Author

Paola Redaelli
M. Pighi

Author

Michele Pighi
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE coronary intravascular lithotripsy catheter meets primary safety and effectiveness endpoints

18 May 2026

Didn’t find what you were looking for?